Bristol-Myers Squibb Company (BMY) Completes Acquisition of KOSAN Biosciences, Inc. (KOSN)
6/27/2008 9:58:09 AM
More...
|
Bristol-Myers Squibb Company (BMY) Completes Tender Offer for KOSAN Biosciences, Inc. (KOSN)
6/26/2008 9:07:30 AM
More...
|
Bristol-Myers Squibb Company (BMY) Announces Expiration of Hart-Scott-Rodino Review Period for Acquisition of KOSAN Biosciences, Inc. (KOSN)
6/18/2008 10:02:30 AM
More...
|
KOSAN Biosciences, Inc. (KOSN)'s Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial; Data Presented at American Society of Clinical Oncology Show 26% Partial Response, 63% Clinical Benefit Incidence
6/3/2008 10:01:02 AM
More...
|
Bristol-Myers Squibb Company (BMY) Begins Tender Offer to Acquire KOSAN Biosciences, Inc. (KOSN)
5/30/2008 10:46:52 AM
More...
|
Bristol-Myers Squibb Company (BMY) to Acquire KOSAN Biosciences, Inc. (KOSN) for $190 Million
5/29/2008 6:46:52 AM
More...
|
KOSAN Biosciences, Inc. (KOSN) Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
5/20/2008 7:15:22 AM
More...
|
KOSAN Biosciences, Inc. (KOSN) Announces Data Presentations at American Society of Clinical Oncology 2008 Annual Meeting
5/14/2008 11:08:50 AM
More...
|
KOSAN Biosciences, Inc. (KOSN) First Quarter 2008 Financial Results
5/2/2008 7:23:06 AM
More...
|
KOSAN Biosciences, Inc. (KOSN) Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results
4/25/2008 8:14:55 AM
More...
|
|